{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:23:46Z","timestamp":1773300226127,"version":"3.50.1"},"reference-count":34,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T00:00:00Z","timestamp":1478822400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004350","name":"Studienstiftung des Deutschen Volkes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["A08580 M10A10647"],"award-info":[{"award-number":["A08580 M10A10647"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["03IS2061A"],"award-info":[{"award-number":["03IS2061A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006010","name":"Bayer Schering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006314","name":"Biogen Idec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006314","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain and Behavior"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Dalfampridine exerts beneficial effects on walking ability in a subgroup of patients with multiple sclerosis (<jats:styled-content style=\"fixed-case\">MS<\/jats:styled-content>). These patients are termed \u201cresponders\u201d. Here, we investigated whether the responder status with respect to mobility measures would determine whether dalfampridine treatment exerts a beneficial effect on other <jats:styled-content style=\"fixed-case\">MS<\/jats:styled-content> symptoms. We therefore assessed walking ability, upper limb function, cognition, fatigue, visual evoked potentials (<jats:styled-content style=\"fixed-case\">VEP<\/jats:styled-content>s), depression, and quality of life in patients before and after dalfampridine treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with <jats:styled-content style=\"fixed-case\">MS<\/jats:styled-content> and impaired mobility were recruited. Maximal walking distance, timed 25 Foot Walk, nine hole peg test, paced auditory serial addition test (<jats:styled-content style=\"fixed-case\">PASAT<\/jats:styled-content>), fatigue severity scale (<jats:styled-content style=\"fixed-case\">FSS<\/jats:styled-content>), <jats:styled-content style=\"fixed-case\">VEP<\/jats:styled-content>s, Beck Depression Inventory (<jats:styled-content style=\"fixed-case\">BDI<\/jats:styled-content>), EuroQol five dimensional questionnaire, and quality of life visual analogue scale were determined before and after 12\u201314\u00a0days of dalfampridine treatment. Repeated measures analysis of variance was applied to determine the effect of dalfampridine treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 34 patients who completed the study, 22 patients were responders and 12 patients nonresponders, according to their performance in mobility measures. Treatment effects for the entire patient cohort were observed for <jats:styled-content style=\"fixed-case\">PASAT<\/jats:styled-content> (<jats:italic>p\u00a0<\/jats:italic>=\u00a0.029) and <jats:styled-content style=\"fixed-case\">BDI<\/jats:styled-content> (<jats:italic>p\u00a0<\/jats:italic>=\u00a0.032). Belonging to the responder cohort did not predict the response to treatment in these tests. For the <jats:styled-content style=\"fixed-case\">FSS<\/jats:styled-content>, response to dalfampridine treatment was dependent on the responder status (<jats:italic>p\u00a0<\/jats:italic>=\u00a0.001) while no effects in the total patient cohort were observed (<jats:italic>p\u00a0<\/jats:italic>=\u00a0.680). Other neurological functions remained unaltered. For <jats:styled-content style=\"fixed-case\">VEP<\/jats:styled-content> latencies, no significant improvements were detected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this study, we observed beneficial effects of dalfampridine on cognition, depression, and fatigue. These effects were not limited to patients who responded to dalfampridine with improved mobility measures. These findings underscore the need to assess the beneficial effects of dalfampridine on neurological deficits in <jats:styled-content style=\"fixed-case\">MS<\/jats:styled-content> patients in additional randomized clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.1002\/brb3.559","type":"journal-article","created":{"date-parts":[[2016,11,16]],"date-time":"2016-11-16T15:18:49Z","timestamp":1479309529000},"source":"Crossref","is-referenced-by-count":22,"title":["Dalfampridine effects on cognition, fatigue, and dexterity"],"prefix":"10.1002","volume":"7","author":[{"given":"Melanie","family":"Korsen","sequence":"first","affiliation":[{"name":"Department of Neurology University Medicine Greifswald  Greifswald Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhina","family":"Kunz","sequence":"additional","affiliation":[{"name":"Department of Neurology University Medicine Greifswald  Greifswald Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Schminke","sequence":"additional","affiliation":[{"name":"Department of Neurology University Medicine Greifswald  Greifswald Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Runge","sequence":"additional","affiliation":[{"name":"Department of Neurology University Medicine Greifswald  Greifswald Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kohlmann","sequence":"additional","affiliation":[{"name":"Institute of Community Medicine University Medicine Greifswald  Greifswald Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Dressel","sequence":"additional","affiliation":[{"name":"Department of Neurology University Medicine Greifswald  Greifswald Germany"},{"name":"Department of Neurology Carl\u2010Thiem\u2010Klinikum Cottbus  Cottbus Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,11,11]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-015-7797-1"},{"key":"e_1_2_8_3_1","unstructured":"Chan A. Flachenecker P. Gold R. Haghikia A. Hellwig K. Hemmer B. \u2026Zipp F.(2012).DGN\/KKNMS Leitlinie zur Diagnose und Therapie der MS. Retrieved fromhttp:\/\/wwwdgnorg\/images\/stories\/dgn\/leitlinien\/LL_MS_Neu\/DGN-KKNMS_MS-LL_20120809_frei_neu4pdf11012013."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/122.5.871"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410270215"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(93)90329-W"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.583229"},{"key":"e_1_2_8_8_1","unstructured":"EuropeanMedicinesAgency. (2011).European public assessment report (EPAR) for Fampyra. Retrieved fromhttp:\/\/wwwemaeuropaeu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002097\/WC500109956pdf25102014."},{"key":"e_1_2_8_9_1","volume-title":"Multiple Sclerosis Functional Composite (MSFC): Administration and scoring manual","author":"Fischer J. S.","year":"2001"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22240"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60442-6"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458506069538"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182929fd5"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514533844"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm2001629"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880030202"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1989.00520460115022"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-11-105"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2015.06.008"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515606809"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000442348"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10865-005-2561-0"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2015.08.023"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22366"},{"key":"e_1_2_8_26_1","first-page":"75","article-title":"Assessing the long\u2010term clinical benefit of prolonged\u2010release fampridine tablets in a real\u2010world setting: a review of 67 cases","volume":"4","author":"Prugger M.","year":"2013","journal-title":"Patient Related Outcome Measures"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01342.x"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1191\/135245801701567050"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2013.11.011"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2015.11.035"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(96)00477-0"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/123.1.171"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.9.1701"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000130"}],"container-title":["Brain and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbrb3.559","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/brb3.559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T16:17:04Z","timestamp":1696609024000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/brb3.559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,11]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1002\/brb3.559"],"URL":"https:\/\/doi.org\/10.1002\/brb3.559","archive":["Portico"],"relation":{},"ISSN":["2162-3279","2162-3279"],"issn-type":[{"value":"2162-3279","type":"print"},{"value":"2162-3279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,11]]},"article-number":"e00559"}}